Trial Profile
A Phase 1 Dose Escalation Open Label Study Of CP-870,893 In Combination With Gemcitabine In Patients With Chemotherapy-Naïve Surgically Incurable Pancreatic Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs CP 870893 (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 04 Mar 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
- 10 Dec 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 10 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.